Now Available for Free Download
What Our Experts Share
- Industry drivers behind manufacturing intensification and the increasing limits of traditional fed‑batch at higher titers and cell densities.
- Core technical elements of intensified fed‑batch systems, including high‑density inoculation and N‑1 perfusion seed strategies.
- Operational impacts across harvest, cell separation, and downstream processing, with approaches to manage intensified product loads.
- Documented improvements in titer, space‑time yield, and production timelines, along with cost, facility footprint, and resource‑use implications.
- Key implementation considerations, including cross‑functional impacts across upstream, downstream, and manufacturing operations.
Download Your Complimentary Copy
Featuring Insights From
Jim Watson
Chief Solutions Officer
Jim Watson is Chief Solutions Officer at Project Farma, where he leads the delivery of capital projects and GMP‑compliant manufacturing facilities for advanced therapies, biologics, and large‑molecule products, partnering across technical, engineering, and regulatory teams to support client readiness and long‑term success.
With over 25 years of experience in the pharmaceutical and biotechnology industries, Jim has led manufacturing strategy, facility design, buildout, and qualification across complex programs. He holds a B.S. in Chemical Engineering from Worcester Polytechnic Institute and is currently completing his MBA at the University of Central Oklahoma.
Greg Sears
VP, Technical Operations
Greg Sears is Vice President of Technical Operations at Project Farma, bringing more than 29 years of experience across CDMO, consulting, and sponsor environments. His expertise spans technical operations, MSAT, CQV, process validation, and commercialization, with a proven record of supporting products through licensure and market approval.
Greg has led large, multidisciplinary teams supporting aseptic manufacturing across advanced modalities including viral vectors, gene therapies, and emerging platforms. His experience includes technology transfer from preclinical through commercial production, regulatory engagement with global health authorities, and delivery of compliant, scalable manufacturing solutions. He holds a B.S. in Chemical Engineering with a minor in Chemistry.
Accelerating Manufacturing for Life-Saving Therapies
Tell us about your project needs and we'll connect you to the right technical expert.